This fusion oncogene encodes BCR‐ABL oncoprotein with constitutive tyrosine kinase activity which can potently transform hematopoietic stem cells (HSCs) into leukemia stem cells (LSCs).[1] The first‐line drugs, tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, dasatinib, and olverembatinib, are highly effective in the treatment of most patients with CML, leading to a normal life expectancy.[2] Nevertheless, disease relapse and progression possibly driven by the persistent LSCs remain a big challenge in the clinic.[3]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.